(UroToday.com) Penile cancer is a rare genitourinary malignancy, affecting less than 1 in 100,000 patients in Western industrialized countries. Platinum chemotherapy is the mainstay of treatment for metastatic penile cancer (disease that has spread outside the pelvis), but unfortunately, disease control is poor, and overall survival in the metastatic setting is typically less than 1 year. Given the rarity of this disease, data regarding patient treatment patterns and outcomes is lacking. In this presentation, Dr. Liu presented treatment, toxicity, and outcomes data from 1200 penile cancer patients referred to a large quarternary academic center in the UK, including 101 patients with metastatic penile carcinoma, 59 of whom received chemotherapy.